Board of Managers
Donald C. Fresne, Founder and Executive Chairman has more than 20 years experience in the biotechnology industry. He was the founder and CEO of Egenix, Inc. Egenix was a privately held, New York based biotechnology company focused on the development of innovative cancer therapeutics.
In addition, Mr. Fresne has extensive management experience in the plastics and chemical industry. He is the former Chairman and CEO at Texas Chemical and Plastics, Inc. and the former Chairman and CEO at Resorcinol PR, Inc.
Paul H. Schwartz, DVM, COO is a Doctor of Veterinary Medicine with extensive practices throughout New York. He is accomplished in the care of small animals and equines. In his practice, he has remained on the forefront with the development of new procedures and technologies in veterinary science.
In addition to developing and managing his Veterinary Centers, Dr. Schwartz is experienced in bringing new technologies to market and running several for profit enterprises. He is currently the President of Equine Nutriceuticals, LLC, in Bloomsbury, NJ, and previously was President of the Veterinary Medical Division of Drug Delivery Systems Inc, NYC, NY.
Dr. Schwartz has a BS in Statistics and a Doctor of Veterinary Medicine from the University of Florida Gainesville, FL. His post Baccalaureate Training includes Advanced Orthopedics Canine/Equine (OSU), and Advanced Ultrasound Imaging/Echocardiography. In addition, he holds certification in Tibial Plateau Leveling (TPLO/Slocum Inst.) and Veterinary Acupuncture (IVAS).
Raphael Nir, PhD
Dr. Nir received his PhD from Tel-Aviv University (Biotechnology; 1990) and Master in Management (1997; NJIT). He has 25 years of experience in the field of cell culture, cell-based assays, protein production and purification, and therapeutic development. Dr. Nir was formerly the Associate Principal Scientist at Schering-Plough Research Institute, where he led the development of several novel processes related to protein production. As the Co-Founder, President and CSO of SBH Sciences, Inc, he manages all of the research and development activities with a focus on the development and implementation of immunoassays and cell-based assays and efficient manufacturing by cell culture of recombinant cytokines and enzymes. Dr. Nir is a world leader in these fields with over 80 processes for recombinant proteins in mammalian and insect cell cultures for commercial use in the R&D market and over 290 bioassays which are currently available in SBH Sciences’ two state-of-the-art cell culture facilities. Currently at SBH Sciences, he is focused on the anti-cancer and anti-inflammation drug development including lead drug optimization to mitigate Glioblastoma and development of a therapy for liver fibrosis by specific targeting of Galectin-3. He is also the CO-Founder of Galectin Sciences, SBH Diagnostics, Woodland Biosciences, Karyopharm Therapeutics, Alma-BioTherapeutics and SKY Ventures International.
John J. McCloy II attended Deerfield Academy and Princeton University. Graduated in 1959. Spent three year in the US Army as an officer. Was stationed in the US and Germany.
Joined Brown Brothers Harriman & Co. in 1962. In 1976, was appointed General Manager of MEFA Financial Consulting Associates. MEFCA was a joint venture owned equally by Brown Brothers Harriman & Co. and the Faisal family of Saudi Arabia. MEFCA’s role was to evaluate and implement projects in the Middle East drawing its clientele from major international companies and from Middle Eastern companies and families. If an evaluation proved the worth of the project to be valid, MEFCA undertook the effort to identify the required funding, the appropriate partner(s) – Arab or non-Arab – and the necessary management structure. MEFCA would extend its involvement until such time as the project was firmly established.
In 1981 returned to Brown Brothers Harriman and resigned in 1982 to pursue private interests.
In 1982 founded J.J. McCloy, Inc. which operated as vehicle for several private investments.
1n 1984 joined McConnell and Miller, an investment manager, which later changed it’s name to Sound Shore Management. Became Chairman of the Sound Shore Fund, a mutual fund owned and operated by Sound Shore Management.
In 1987 resigned to become the Chairman and CEO of Noise Cancellation Technologies, (NCT), a company which electronically cancelled noise and vibration. Over the next eight years, formed joint development ventures with over a dozen major international corporations focused on reducing noise and vibration in a wide variety of applications.
In 2006 joined, as General Manager, Nicholson International, an executive recruitment firm based in London. While in London met the founder of Mondial, Inc. a technology firm based in New York. When asked to become its Chairman in 2008, moved back to New York. Mondial reconstituted itself and reopened its doors as Gravitas Technology. Resumed the role of Chairman of Gravitas until retirement in 2012.
Have worked as a consultant and entrepreneur to the present.
Member of the Council on Foreign Relations, Round Hill Club, The Everglades Club and the Bath and Tennis Club. Married with two children. Tennis, skiing, hunting and fishing are the principle pastimes.